The single arm clinical study is to evaluate the efficacy and safety of Tislelizumab combined with Bevacizumab and albumin paclitaxel in the treatment of advanced lung adenocarcinoma. All of the patients were received EGFR-TKI therapy for 1 line and disease progression. The primary endpoint is one-year PFS rate and safety, the seconday endpoint is ORR and one-year OS rate.
Name: Tislelizumab
Description: rate of progression free survical in one year
Measure: PFS rate Time: one yearDescription: TEAE are adverse events that occur during or after the first administration of the study drug until 30 days after the study drug is discontinued or the new anticancer treatment is initiated or worse than at baseline (before treatment)
Measure: Safety of Tislelizumab Time: 30 days after the trial finishedDescription: objective response rate
Measure: ORR Time: one yearDescription: rate of oversurvival rate
Measure: OS rate Time: one yearAllocation: N/A
Single Group Assignment
There is one SNP
Inclusion Criteria: - lung adenocarcinoma stage Ⅳ(according AJCC 8) - received EGFR-TKI for 1 line and disease progression - EGFR T790M negative - ECOG PS 0-1 Exclusion Criteria: - histology of mixed NSCLC with squamous cell carcinoma, neuroendocrine carcinoma and small cell carcinoma. --- T790M ---
- uncontrolled pleural effusion, pericardial effusion, or ascites after appropriate intervention - any unstable systemic disease - patients who were treated with systemic glucocorticoids (>10mg/ day prednisone therapeutic dose) or other immunosuppressive drugs within 14 days prior to the initial administration or during the study period Inclusion Criteria: - lung adenocarcinoma stage Ⅳ(according AJCC 8) - received EGFR-TKI for 1 line and disease progression - EGFR T790M negative - ECOG PS 0-1 Exclusion Criteria: - histology of mixed NSCLC with squamous cell carcinoma, neuroendocrine carcinoma and small cell carcinoma. --- T790M ---